

**Product Monograph  
Including Patient Medication Information**

**Pr TARO-WARFARIN**

Warfarin Sodium Tablets

Immediate Release Tablets, For Oral Use

1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg of Warfarin Sodium

USP

Anticoagulant

Taro Pharmaceuticals Inc.

Date of Authorization: 2026-04-08

130 East Drive

Brampton, Ontario L6T 1C1

Control No.: 299721

**Recent Major Label Changes**

<a href="#">7 Warnings and Precautions, Renal</a>	04/2026
---	---------

**Table of Contents**

Certain sections or subsections that are not applicable at the time of the reparation of the most recent authorized product monograph are not listed.

Recent Major Label Changes .....2

Part 1: Healthcare Professional Information .....4

1 Indications .....4

    1.1 Pediatrics (<18 years of age) ..... 4

    1.2 Geriatric Patients (≥ 65 years of age) ..... 4

2 Contraindications .....4

3 Serious Warnings and Precautions Box.....5

4 Dosage and Administration .....6

    4.1 Dosing Considerations ..... 6

    4.2 Recommended Dose and Dosage Adjustment..... 6

    4.4 Administration ..... 9

    4.5 Missed Dose..... 9

5 Overdose .....9

6 Dosage Forms, Strengths, Composition and Packaging ..... 10

7 Warnings and Precautions ..... 11

    Endocrine and Metabolism..... 13

    Immune ..... 15

    7.1 Special Populations..... 17

        7.1.1 Pregnancy..... 17

        7.1.2 Breastfeeding ..... 17

        7.1.3 Pediatrics..... 18

        7.1.4 Geriatrics (≥ 60 years of age):..... 18

8 Adverse Reactions ..... 19

    8.1 Adverse Reaction Overview ..... 19

    8.5 Post-marketing Adverse reactions ..... 20

9 Drug Interactions.....21

    9.2 Drug Interactions Overview ..... 21

9.4 Drug-Drug Interactions .....	21
9.5 Drug-Food Interactions.....	27
9.6 Drug-Herb Interactions .....	27
9.7 Drug-Laboratory Test Interactions.....	29
10 Clinical Pharmacology .....	29
10.1 Mechanism of Action .....	29
10.2 Pharmacodynamics.....	29
10.3 Pharmacokinetics.....	30
11 Storage, Stability, and Disposal.....	32
12 Special Handling Instructions .....	32
PART II: SCIENTIFIC INFORMATION.....	34
13 Pharmaceutical Information.....	34
14 Clinical Trials .....	34
14.1 Clinical Trial by Indication .....	34
14.2 Comparative Bioavailability Studies.....	34
15 Microbiology.....	39
16 Non-Clinical Toxicology .....	39
17 Supporting Product Monograph .....	39
PATIENT MEDICATION INFORMATION.....	40

## Part 1: Healthcare Professional Information

### 1 Indications

TARO-WARFARIN (warfarin sodium) tablets are indicated for:

- Prophylaxis and/or treatment of venous thrombosis and its extension,
- Pulmonary embolism,
- Atrial fibrillation with embolization, and
- As an adjunct in the prophylaxis of systemic embolism after myocardial infarction, including stroke and reinfarction.

The following are some of the more common clinical disorders which may be associated with or predispose patients to the above indications:

1. Thrombophlebitis
2. Congestive heart failure
3. Surgical procedure or trauma associated with a high risk of thromboembolism
4. Myocardial infarction
5. Cerebral embolism

It may also be useful as an adjunct in the treatment of transient cerebral ischemic attacks due to intravascular clotting.

#### 1.1 Pediatrics (<18 years of age)

Based on the data submitted and reviewed by Health Canada, the safety and efficacy of TARO-WARFARIN pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use (see [7 Warnings and Precautions, 7.1.3 Pediatrics](#)).

#### 1.2 Geriatric Patients (≥ 65 years of age)

Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. (see [7 Warnings and Precautions, 7.1.4. Geriatrics](#)).

### 2 Contraindications

TARO-WARFARIN is contraindicated in:

- Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 Dosage Forms, Strengths, Composition, and Packaging](#).

TARO-WARFARIN is contraindicated in any localized or general physical condition or personal circumstances in which the hazard of haemorrhage might be greater than the potential clinical benefits of anticoagulation, such as:

- Pregnancy

TARO-WARFARIN (warfarin sodium) is contraindicated in pregnancy because the drug passes through the placental barrier and may cause fatal haemorrhage to the fetus in utero. Women of childbearing potential must take precautions not to become pregnant while on TARO-WARFARIN therapy. Furthermore, there have been reports of birth malformations in children born to mothers who have been treated with warfarin during pregnancy. See [7.1.1 Pregnancy](#).
- Haemorrhagic tendencies or blood dyscrasias
- Recent or contemplated surgery of:
  1. central nervous system
  2. eye
  3. traumatic surgery resulting in large open surfaces
- Bleeding tendencies associated with active ulceration or overt bleeding of:
  1. gastrointestinal, genitourinary or respiratory tracts
  2. central nervous system haemorrhage
  3. cerebral aneurysms or dissecting aorta
  4. pericarditis and pericardial effusions
  5. bacterial endocarditis
- Threatened abortion, eclampsia and preeclampsia
- Inadequate laboratory facilities
- Unsupervised patients with conditions associated with potential high level of noncompliance such as senility, alcoholism, or psychosis or other lack of patient cooperation
- Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding
- Major regional or lumbar block anesthesia
- Malignant hypertension

### 3 Serious Warnings and Precautions Box

**BLEEDING RISK:** Warfarin sodium can cause major or fatal bleeding. Bleeding is more likely to occur during the starting period and with a higher dose (resulting in a higher INR). Risk factors for bleeding include high intensity of anticoagulation (INR > 4.0), age > 65, highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs (see [7 Warnings and Precautions, Hematologic](#) and [9.4 Drug-Drug Interactions](#)), and long duration of warfarin therapy. Regular monitoring of INR should be performed on all treated patients. Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shorter duration of therapy appropriate for the clinical condition. However, maintenance of INR in the therapeutic range does not eliminate the risk of bleeding. Drugs, dietary changes, and other factors affect INR levels achieved with **TARO-WARFARIN** therapy. Perform more frequent INR monitoring when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs. Patients should be instructed about prevention measures to minimize risk of bleeding and to report immediately to physicians' signs and symptoms of bleeding. (see [7 Warnings and Precautions](#))

**An INR of greater than 4.0 appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of pathological bleeding.**

## 4 Dosage and Administration

### 4.1 Dosing Considerations

The administration and dosage of TARO-WARFARIN (warfarin sodium) tablets must be individualized according to the patient's responsiveness to the drug. The dosage should be adjusted according to results of the patient's PT ratio/INR. Measurement of warfarin induced effects on PT can vary substantially due to the sensitivity of different thromboplastin reagents.

Early clinical studies of oral anticoagulants, which formed the basis for recommended therapeutic ranges of 1.5 to 2.5 times control PT, used sensitive human brain thromboplastin. When using the less sensitive rabbit brain thromboplastins commonly employed in PT assays today, adjustments must be made to the targeted PT range that reflect this decrease in sensitivity.

### 4.2 Recommended Dose and Dosage Adjustment

The best available information supports the following recommendations for dosing of TARO-WARFARIN Tablets.

#### **Venous Thromboembolism (including deep venous thrombosis [DVT] and pulmonary embolism [PE])**

For patients with a first episode of DVT or PE secondary to a transient (reversible) risk factor, treatment with warfarin for 3 months is generally recommended. For patients with a first episode of idiopathic DVT or PE, warfarin is generally recommended for at least 6 to 12 months. For patients with two or more episodes of documented DVT or PE, indefinite treatment with warfarin is suggested. For patients with specific risk factors (e.g. documented antiphospholipid antibodies), please refer to current

treatment guidelines for recommended duration of treatment.

The dose of warfarin should be adjusted to maintain a target INR of 2.5 (INR range, 2.0 to 3.0) for all treatment durations.

### **Atrial Fibrillation**

Five recent clinical trials evaluated the effects of warfarin in patients with non-valvular atrial fibrillation (AF). Findings of these studies revealed that the effects of warfarin in reducing thromboembolic events including stroke were similar at either moderately high INR (2.0-4.5) or low INR (1.4-3.0). There was a significant reduction in minor bleeds at the low INR. There are no adequate and well-controlled studies in populations with atrial fibrillation and valvular heart disease. Although clinical studies have used a wide range of warfarin dosing, a more recent study suggests that in patients with atrial fibrillation, anticoagulant prophylaxis is effective at INRs of 2.0 to 3.0. The study also shows that the risk of thromboembolic stroke may increase substantially at INR's less than 2.0. INR value should not exceed 4.0, to reduce the risk of anticoagulant-related bleeding.

Similar data from clinical studies in valvular atrial fibrillation patients are not available. The trials in non-valvular atrial fibrillation support the recommendation that an INR of 2.0-3.0 be used for long term warfarin therapy in appropriate AF patients. In cases where the risk of thromboembolism is great, such as in patients with recurrent systemic embolism, a higher INR may be required. An INR ratio of greater than 4.0 appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of bleeding. In AF patients undergoing elective cardioversion, anticoagulant therapy should be given for three weeks before cardioversion and continued until normal sinus rhythm has been maintained for four weeks.

Oral anticoagulation is recommended in patients with persistent or paroxysmal atrial fibrillation without valvular disease but at high risk of embolic stroke, i.e., having any of the following features: prior ischemic stroke, transient ischemic attack, or systemic embolism; age >75 years; moderately or severely impaired left ventricular systolic function or congestive heart failure, history of hypertension, or diabetes mellitus. For patients at lower risk, individualized treatment is required. For patients with atrial fibrillation and valvular heart disease, especially mitral valve stenosis, anticoagulation is recommended. For patients with atrial fibrillation and prosthetic heart valves, anticoagulation is required, with the target INR generally increased, with or without aspirin added, depending of risk factors related to the replaced valve or inherent to the patient.

### **Post-Myocardial Infarction**

For most patients following myocardial infarction and not at high risk, antithrombotic treatment should consist of aspirin alone. In patients with acute coronary syndrome that were revascularised by percutaneous coronary intervention (PCI), clopidogrel is usually added. For high-risk patients with myocardial infarction (MI), including those with a large anterior MI, significant heart failure, intracardiac thrombus visible on echocardiography, or those with a history of a thromboembolic event, therapy with combined moderate-intensity warfarin (INR 2.0 to 3.0) plus low-dose aspirin (100 mg/day) for 3 months following myocardial infarction should be considered.

**Renal Impairment**

While no dosage adjustment is necessary for patients with renal failure, frequent monitoring of anticoagulation is advised in patients with compromised renal function to maintain warfarin dosage within the therapeutic range (see [7 Warnings and Precautions](#)).

**Laboratory Control**

The Prothrombin Time (PT) should be determined daily after the administration of the initial dose until International Normalized Ratio (INR) results stabilize in the therapeutic range. Intervals between subsequent INR determinations should be based upon the physician's judgment of the patient's reliability and response to warfarin in order to maintain the individual within the therapeutic range. Acceptable intervals for INR determinations are normally within the range of one to four weeks after a stable dosage has been determined.

To ensure adequate control, it is recommended that additional PT tests be done when other warfarin products are interchanged with warfarin sodium tablets, as well as whenever other medications are initiated, discontinued, or taken irregularly (see [7 Warnings and Precautions](#)). Safety and efficacy of warfarin therapy can be improved by increasing the quality of laboratory control. Reports suggest that in usual care monitoring, patients are in therapeutic range only 33%-64% of the time. Time in therapeutic range is significantly greater (56%-93%) in patients managed by anticoagulation clinics.

In switching to another warfarin product, particular emphasis needs to be placed on INR control. INR outside of the therapeutic range may result in serious clinical consequences: lack of efficacy leading to thromboembolic stroke or myocardial infarction, if INR values are low, and intracranial bleeding if they are high.

**Initial Dosage**

The dosing of TARO-WARFARIN Tablets must be individualized according to the patient's sensitivity to the drug as indicated by the PT/ INR. Use of a large loading dose may increase the incidence of hemorrhagic and other complications, does not offer more rapid protection against thrombi formation, and is not recommended. It is recommended that TARO-WARFARIN Tablets therapy be initiated with a dose of 2 to 5 mg per day with dosage adjustments based on the results of PT/INR determinations. The lower initiation doses should be considered for patients with certain genetic variations in CYP2C9 and VKORC1 enzymes as well as for elderly and/or debilitated patients and patients with potential to exhibit greater than expected PT/INR responses to TARO-WARFARIN Tablets. Elderly and Asian patients may require lower initiation and maintenance doses of TARO-WARFARIN Tablets (see [7 Warnings and Precautions](#)).

**Maintenance**

Most patients are satisfactorily maintained at a dose of 2 to 10 mg daily. Flexibility of dosage is provided by breaking scored tablets in half. The individual dose and interval should be gauged by the patient's prothrombin response.

**Duration of Therapy**

The duration of therapy in each patient should be individualized. In general, anticoagulant therapy should be continued until the danger of thrombosis and embolism has passed.

**4.4 Administration**

TARO-WARFARIN (warfarin sodium) tablets are for oral use only. Administer at the same time each day, with or without food.

**4.5 Missed Dose**

The anticoagulant effect of TARO-WARFARIN Tablets persists beyond 24 hours. If the patient forgets to take the prescribed dose of TARO-WARFARIN Tablets at the scheduled time, the dose should be taken as soon as possible on the same day. The patient should not take the missed dose by doubling the daily dose to make up for missed doses, but should refer back to his or her physician.

**5 Overdose****Signs and Symptoms**

Suspected or overt abnormal bleeding (e.g., appearance of blood in stools or urine, haematuria, excessive menstrual bleeding, melena, petechiae, excessive bruising or persistent oozing from superficial injuries) unexplained fall in hemoglobin) is a manifestation of excessive anticoagulation.

**Treatment**

The treatment of excessive anticoagulation is based on the level of the INR, the presence or absence of bleeding, and clinical circumstances. Excessive anticoagulation, may be controlled by discontinuing TARO-WARFARIN (warfarin sodium) tablet therapy and if necessary, by administration of oral or parenteral vitamin K<sub>1</sub>. (Please see recommendations accompanying vitamin K<sub>1</sub> preparations prior to use.)

Such use of vitamin K<sub>1</sub> reduces responses to subsequent TARO-WARFARIN Tablets therapy. Patients may return to a pretreatment thrombotic status following the rapid reversal of a prolonged INR. Resumption of warfarin administration reverses the effect of vitamin K<sub>1</sub>, and a therapeutic INR can again be obtained by careful dosage adjustment. If rapid anticoagulation is indicated, heparin may be preferable for initial therapy.

If minor bleeding progresses to major bleeding, give 5 to 25 mg (rarely up to 50 mg) parenteral vitamin K<sub>1</sub>. Prothrombin complex concentrate (PCC), fresh frozen plasma, or activated Factor VII treatment may be considered if the requirement to reverse the effects of Taro-Warfarin Tablets is urgent.

A risk of hepatitis and other viral diseases is associated with the use of these blood products; PCC and activated Factor VII are also associated with an increased risk of thrombosis. Therefore, these preparations should be used only in exceptional or life-threatening bleeding episodes secondary to TARO-WARFARIN Tablet overdosage.

Purified Factor IX preparations should not be used because they cannot increase the levels of prothrombin, Factor VII and Factor X, which are also depressed along with the levels of Factor IX as a result of TARO-WARFARIN Tablet treatment. Packed red blood cells may also be given if significant blood loss has occurred. Infusions of blood or plasma should be monitored carefully to avoid precipitating pulmonary edema in elderly patients or patients with heart disease.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

## 6 Dosage Forms, Strengths, Composition and Packaging

**Table 1- Dosage Forms, Strengths, and Composition**

Route of Administration	Dosage Form/ Strength/Composition	Non-Medicinal Ingredients
Oral	Tablet 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg of warfarin sodium	<p>Non-medicinal ingredients: magnesium stearate, lactose anhydrous, pregelatinized corn starch and colour dye which varies in each tablet strength.</p> <p>Use of colour dyes varies by tablet strength:</p> <p>1 mg: D&amp;C Red #6 - Lake</p> <p>2 mg: FD&amp;C Blue #2 - Lake and FD&amp;C Red #40 - Lake</p> <p>2.5 mg: FD&amp;C Blue #2 - Lake and D&amp;C Yellow #10 - Lake</p> <p>3 mg: FD&amp;C Red #40 - Lake, D&amp;C Yellow #10 - Lake and FD&amp;C Blue #2 - Lake</p> <p>4 mg: FD&amp;C Blue # 1- Lake</p> <p>5 mg: D&amp;C Yellow #10 - Lake and D&amp;C Red #6 - Lake</p> <p>6 mg: D&amp;C Yellow #10 - Lake and FD&amp;C Blue #2 - Lake</p> <p>7.5 mg: D&amp;C Yellow #10 - Lake</p> <p>10 mg: Dye free</p>

### Description

TARO-WARFARIN (warfarin sodium) tablets, USP are single-scored and engraved as follows:

Strength	Imprint Side 1	Imprint Side 2	Color
1.0 mg	WARFARIN 1	TARO	Pink
2.0 mg	WARFARIN 2	TARO	Lavender
2.5 mg	WARFARIN 2½	TARO	Green

3.0 mg	WARFARIN 3	TARO	Tan
4.0 mg	WARFARIN 4	TARO	Blue
5.0 mg	WARFARIN 5	TARO	Peach
6.0 mg	WARFARIN 6	TARO	Teal
7.5 mg	WARFARIN 7½	TARO	Yellow
10.0 mg	WARFARIN 10	TARO	White

Supplied in bottles and blister packs of 100 for the 1, 2, 2.5, 3, 4, 5, 6, 7.5 and 10 mg strengths.  
 Supplied in bottles of 250 for the 1, 2, 2.5, 4 and 5 mg strengths.  
 Supplied in bottles of 1000 for the 1, 2, 2.5, 3, 4, 5 and 6 mg strengths.

## 7 Warnings and Precautions

Please see [3 Serious Warnings and Precautions Box](#)

### General

**It cannot be emphasized too strongly that treatment of each patient is a highly individualized matter.** TARO-WARFARIN Tablets, a narrow therapeutic range (index) drug, may be affected by factors such as other drugs and dietary Vitamin K. Dosage should be controlled by periodic determinations of prothrombin times (PT) ratio/ International Normalized Ratio (INR) or other suitable coagulation tests. Determinations of whole blood clotting and bleeding times are not effective measures for control of therapy. Heparin prolongs the one-stage PT. When heparin and TARO-WARFARIN Tablets are administered concomitantly, refer below to CONVERSION FROM HEPARIN THERAPY for recommendations.

Concomitant use of anticoagulants with streptokinase or urokinase is not recommended and may be hazardous. (Please note recommendations accompanying these preparations).

In patients with acquired or inherited warfarin resistance, decreased therapeutic responses to warfarin sodium tablets have been reported. Exaggerated therapeutic responses have been reported in other patients.

Consult the labeling of all concurrently used drugs to obtain further information about interactions with TARO-WARFARIN or adverse reactions pertaining to bleeding

### Cardiovascular

Patients with congestive heart failure may become more responsive to TARO-WARFARIN Tablets, thereby requiring more frequent laboratory monitoring, and reduced doses of TARO-WARFARIN Tablets.

### Systemic atheroemboli and cholesterol microemboli

Anticoagulation therapy with TARO-WARFARIN Tablets may enhance the release of atheromatous plaque emboli, thereby increasing the risk of complications from systemic cholesterol microembolization, including the "purple toe syndrome". While the "purple toe syndrome" is reported to be reversible, other complications of microembolization may not be reversible.

Systemic atheroemboli and cholesterol microemboli can present with a variety of signs and symptoms including purple toes syndrome, livedo reticularis, rash, gangrene, abrupt and intense pain in the leg, foot, or toes, foot ulcers, myalgia, penile gangrene, abdominal pain, flank or back pain, hematuria, renal insufficiency, hypertension, cerebral ischemia, spinal cord infarction, pancreatitis, symptoms simulating polyarteritis, or any other sequelae of vascular compromise due to embolic occlusion. The most commonly involved visceral organs are the kidneys followed by the pancreas, spleen, and liver. Some cases have progressed to necrosis or death. Discontinue TARO-WARFARIN therapy if such phenomena are observed. Consider alternative drugs if continued anticoagulation therapy is necessary.

Purple toe syndrome is a complication of oral anticoagulation characterized by a dark, purplish or mottled color of the toe, usually occurring between 3-10 weeks, or later, after the initiation of therapy with warfarin or related compounds. Major features of this syndrome include purple color of plantar surfaces and sides of the toes that blanches on moderate pressure and fades with elevation of the legs; pain and tenderness of the toes; waxing and waning of the color over time. While the purple toes syndrome is reported to be reversible, some cases progress to gangrene or necrosis which may require debridement of the affected area, or may lead to amputation.

A severe elevation (>50 seconds) in activated partial thromboplastin time (aPTT) with a PT ratio/INR in the desired range has been identified as an indication of increased risk of postoperative haemorrhage. This has been noted in patients undergoing elective hip surgery receiving warfarin alone.

Administration of anticoagulants in the following conditions will be based upon clinical judgement in which the risks of anticoagulant therapy are weighed against the risk of thrombosis or embolization in untreated cases. The following may be associated with these increased risks:

1. Severe to moderate hepatic impairment or renal insufficiency.
2. Infectious diseases or disturbances of intestinal flora, such as sprue or as seen with antibiotic use.
3. Trauma which may result in internal bleeding.
4. Surgery or trauma resulting in large exposed raw surfaces.
5. Indwelling catheters.
6. Severe to moderate hypertension.
7. Deficiency in protein C-mediated anticoagulant response: TARO-WARFARIN reduces the synthesis of the naturally occurring anticoagulants, protein C and protein S. Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Not all patients with these conditions develop necrosis, and tissue necrosis occurs in patients without these deficiencies. Inherited resistance to activated protein C has been described in many patients with venous thromboembolic

disorders but has not yet been evaluated as a risk factor for tissue necrosis. The risk associated with these conditions, both for recurrent thrombosis and for adverse reactions, is difficult to evaluate since it does not appear to be the same for everyone. Decisions about testing and therapy must be made on an individual basis. It has been reported that concomitant anticoagulation therapy with heparin for 5 to 7 days during initiation of therapy with warfarin sodium tablets may minimize the incidence of tissue necrosis. Warfarin therapy should be discontinued when warfarin is suspected to be the cause of developing necrosis and heparin therapy may be considered for anticoagulation.

8. Eye surgery: In cataract surgery, Warfarin tablets use was associated with a significant increase in minor complications of sharp needle and local anesthesia block, but not associated with potentially sight-threatening operative hemorrhagic complications. As Warfarin tablets cessation or reduction may lead to serious thromboembolic complications, the decision to discontinue TARO-WARFARIN before a relatively less invasive and complex eye surgery, such as lens surgery, should be based upon the risks of anticoagulant therapy weighed against the benefits.
9. Diseases affecting the microvasculature or microcirculation, such as polycythemia vera, vasculitis, and severe diabetes.
10. Poor nutritional state.
11. Vitamin K deficiency.
12. Increased vitamin K intake.
13. Hereditary warfarin resistance.

### **Conversion from Heparin Therapy**

Since the anticoagulant effect of TARO-WARFARIN Tablet is delayed; heparin is preferred initially for rapid anticoagulation. Conversion to TARO-WARFARIN Tablets may begin concomitantly with heparin therapy or may be delayed 3 to 6 days. To ensure continuous anticoagulation, it is advisable to continue full dose heparin therapy and that TARO-WARFARIN Tablet therapy be overlapped with heparin for 4 to 5 days, until TARO-WARFARIN Tablet has produced the desired therapeutic response as determined by PT ratio/INR. When TARO-WARFARIN Tablet has produced the desired PT ratio/INR or prothrombin activity, heparin may be discontinued.

TARO-WARFARIN Tablets may increase the aPTT test even in the absence of heparin. During initial therapy with TARO-WARFARIN Tablets, the interference with heparin anticoagulation is of minimal clinical significance.

As heparin may affect the PT, patients receiving both heparin and TARO-WARFARIN Tablets should have blood drawn for PT ratio/INR determination, at least:

- **5 hours after the last IV bolus dose of heparin, or**
- **4 hours after cessation of a continuous IV infusion of heparin, or**
- **24 hours after last subcutaneous heparin injection.**

### **Endocrine and Metabolism**

#### **Calciphylaxis**

Calciphylaxis, also known as calcific uremic arteriolopathy, has been reported in predisposed patients, mainly end-stage renal disease (ESRD) patients under dialysis, but also patients with known risk factors such as hyperphosphatemia, hypercalcemia, low serum albumin levels or receiving vitamin K antagonists, including warfarin. When calciphylaxis is diagnosed in these patients, discontinue TARO-WARFARIN, start specific calciphylaxis supportive treatments, and consider if continued alternative anticoagulation therapy is necessary.

## Hematologic

### Haemorrhage

The most serious risk associated with anticoagulant therapy with TARO-WARFARIN (warfarin sodium) tablets is haemorrhage in any tissue or organ (see [3 Serious Warnings and Precautions Box](#)). The risk of haemorrhage is related to the level of intensity and the duration of anticoagulant therapy.

Haemorrhage has in some cases been reported to result in death or permanent disability.

### Heparin-Induced Thrombocytopenia

Do not use TARO-WARFARIN as initial therapy in patients with heparin-induced thrombocytopenia (HIT) and with heparin-induced thrombocytopenia with thrombosis syndrome (HITTS). Cases of limb ischemia, necrosis, and gangrene have occurred in patients with HIT and HITTS when heparin treatment was discontinued and warfarin therapy was started or continued especially when large initiation doses were used. In some patients sequelae have included amputation of the involved area and/or death. The use of alternative anticoagulant therapy should be considered in patients with heparin-induced thrombocytopenia and deep vein thrombosis. Treatment with TARO-WARFARIN may be considered after the platelet count has normalized.

### Considerations for Increased Bleeding Risk

Warfarin is a narrow therapeutic range (index) drug, and additional caution should be observed when warfarin sodium is administered to certain patients. Reported risk factors for bleeding include high intensity of anticoagulation (INR >4.0), age > 65, highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs (see [7 Warnings and Precautions](#)) and long duration of warfarin therapy. Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses (see [10 Clinical Pharmacology: Metabolism and 4 Dosage and Administration](#)). Bleeding is more likely to occur during the starting period and with a higher dose of warfarin sodium (resulting in a higher INR).

Intramuscular (I.M.) injections of concomitant medications should be confined to the upper extremities which permit easy access for manual compression, inspections for bleeding and use of pressure bandages.

Caution should be observed when warfarin sodium (or warfarin) is administered concomitantly with nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, to be certain that no change in anticoagulation dosage is required. In addition to specific drug interactions that might affect PT/INR, NSAIDs, including aspirin, can inhibit platelet aggregation, and can cause gastrointestinal bleeding,

peptic ulceration and/or perforation.

### **Immune**

Minor and severe allergic/hypersensitivity reactions and anaphylactic reactions have been reported.

### **Monitoring and Laboratory Tests.**

Periodic determination of PT ratio/INR or other suitable coagulation test is essential (see [4 Dosage and Administration: Laboratory Control](#)).

Numerous factors, alone or in combination, including travel, changes in diet, environment, physical state or medication, or the use of natural medicines, may influence the patient's response to anticoagulants including warfarin. It is generally good practice to monitor the patient's response with additional PT ratio/INR determinations in the period immediately after discharge from the hospital, and whenever other medications, including natural medicines, are initiated, discontinued or taken irregularly. This includes drugs intended for short-term use (eg, antibiotics, antifungals, corticosteroids). The following tables in this section provide a listing of factors, alone or in combination, which may affect the PT. However, other factors may also affect the anticoagulant response and the tables are provided for your reference only.

Drugs may interact with warfarin sodium through pharmacodynamic or pharmacokinetic mechanisms. Pharmacodynamic mechanisms for drug interactions with warfarin sodium tablets are synergism (impaired hemostasis, reduced clotting factor synthesis), competitive antagonism (vitamin K), and altered physiologic control loop for vitamin K metabolism (hereditary resistance). Pharmacokinetic mechanisms for drug interactions with warfarin sodium tablets are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. It is important to note that some drugs may interact by more than one mechanism.

Because a patient may be exposed to a combination of listed factors, the net effect of warfarin sodium tablets on PT ratio/INR responses may be unpredictable. More frequent PT/INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids). See [9 Drug Interactions](#)

### **Renal**

#### **Anticoagulant-related nephropathy**

There have been post-marketing reports of anticoagulant-related nephropathy (ARN) following **warfarin** use, presenting as acute kidney injury. Close monitoring including renal function evaluation is advised in patients with a supratherapeutic INR, and hematuria.

#### **Renal impairment**

Patients with renal impairment who are taking warfarin should be instructed to be more vigilant in monitoring their INR

**Use in Patients with altered glomerular integrity**

In patients with altered glomerular integrity or with a history of kidney disease, acute kidney injury may occur, possibly in relation to episodes of excessive anticoagulation and hematuria. See [4.1 Dosing Considerations, Renal Impairment](#).

**Skin****Tissue Necrosis**

Caution should be observed when TARO-WARFARIN Tablets are administered in any situation or in the presence of any predisposing condition where added risk of haemorrhage, necrosis and/or gangrene is present.

Necrosis and/or gangrene of skin and other tissues is an uncommon but serious risk (<0.1%). It may be associated with local thrombosis and usually appears within a few days of the start of TARO-WARFARIN therapy. In severe cases of necrosis, treatment through debridement or amputation of the affected tissue, limb, breast or penis has been reported. Necrosis has in some cases been reported to result in death or permanent disability.

Careful clinical evaluation is required to determine whether necrosis is caused by an underlying disease. Warfarin therapy should be discontinued when warfarin is suspected to be the cause of developing necrosis and heparin therapy may be considered for anticoagulation. Although various treatments have been attempted, no treatment for necrosis has been considered uniformly effective. See below for information on predisposing conditions. These and other risks associated with anticoagulant therapy must be weighed against the risk of thrombosis or embolization in untreated cases. Discontinue TARO-WARFARIN therapy if necrosis occurs. Consider alternative drugs if continued anticoagulation therapy is necessary.

**Perioperative Considerations (Treatment during Dentistry and Surgery)**

The management of patients who undergo dental and surgical procedures requires close liaison between attending physicians, surgeons and dentists. PT ratio/INR determination is recommended just prior to any dental or surgical procedure. In patients undergoing minimal invasive procedures who must be anticoagulated prior to, during, or immediately following these procedures, adjusting the dosage of TARO-WARFARIN Tablets to maintain the PT ratio/INR at the low end of the therapeutic range, may safely allow for continued anticoagulation. The operative site should be sufficiently limited and accessible to permit the effective use of local procedures for haemostasis. Under these conditions, dental and surgical procedures may be performed without undue risk of haemorrhage. Some dental or surgical procedures may necessitate the interruption of TARO-WARFARIN Tablet therapy. When discontinuing TARO-WARFARIN Tablets even for a short period of time, the benefits and risks should be strongly considered.

Some dental or surgical procedures may necessitate the interruption or change in the dose of TARO-WARFARIN therapy. Consider the benefits and risks when discontinuing TARO-WARFARIN even for a short period of time. Determine the INR immediately prior to any dental

or surgical procedure. In patients undergoing minimally invasive procedures who must be anticoagulated prior to, during, or immediately following these procedures, adjusting the dosage of TARO-WARFARIN to maintain the INR at the low end of the therapeutic range may safely allow for continued anticoagulation.

## 7.1 Special Populations

### 7.1.1 Pregnancy

TARO-WARFARIN (warfarin sodium) is contraindicated in pregnancy. In humans, warfarin crosses the placenta, and concentrations in fetal plasma approach the maternal values and may cause fatal haemorrhage to the fetus *in utero*. TARO-WARFARIN exposure during pregnancy can cause pregnancy loss, birth defects, or fetal death. Furthermore, there have been reports of birth malformations in children born to mothers who have been treated with warfarin during pregnancy. Women of childbearing potential must take precautions not to become pregnant while on TARO-WARFARIN therapy. Discuss pregnancy planning with females of reproductive potential who are on TARO-WARFARIN therapy (see [2 Contraindications, Pregnancy](#)).

Exposure to warfarin during the first trimester of pregnancy caused a pattern of congenital malformations in about 5% of exposed offspring. Warfarin embryopathy is characterized by nasal hypoplasia with or without stippled epiphyses (chondrodysplasia punctata) and growth retardation (including low birth weight). Central nervous system and eye abnormalities have also been reported, including dorsal midline dysplasia characterized by agenesis of the corpus callosum, Dandy-Walker malformation, midline cerebellar atrophy, and ventral midline dysplasia characterized by optic atrophy. Mental retardation, blindness, schizencephaly, microcephaly, hydrocephalus, and other adverse pregnancy outcomes have been reported following warfarin exposure during the second and third trimesters of pregnancy (See [2 Contraindications](#)). Although rare, teratogenic reports following in utero exposure to warfarin also include urinary tract anomalies such as single kidney, asplenia, anencephaly, spina bifida, cranial nerve palsy, cardiac defects and congenital heart disease, polydactyly, deformities of toes, diaphragmatic hernia, corneal leukoma, cleft palate and cleft lip.

Spontaneous abortion and still birth are known to occur and a higher risk of fetal mortality is associated with the use of warfarin. Low birth weight and growth retardation have also been reported.

Women of childbearing potential who are candidates for anticoagulant therapy should be carefully evaluated and the indications critically reviewed with the patient. If the patient becomes pregnant while taking this drug, she should be apprised of the potential risks to the fetus, and the possibility of termination of the pregnancy should be discussed in the light of those risks.

### 7.1.2 Breastfeeding

Based on published data in 15 nursing mothers, warfarin was not detected in human milk. Among the 15 full-term newborns, 6 nursing infants had documented prothrombin times within the expected range. Prothrombin times were not obtained for the other 9 nursing infants. Monitor breastfeeding infants for bruising or bleeding. Effects in premature infants have not been evaluated. Caution should be exercised when TARO-WARFARIN is administered to a nursing woman. The decision to breastfeed should be undertaken only after careful consideration of the available alternatives. Women who are breastfeeding and anticoagulated with warfarin should be very carefully monitored so that recommended INR values are not exceeded. It is prudent to perform coagulation tests on infants at risk for bleeding before advising women taking warfarin to breastfeed.

### 7.1.3 Pediatrics

Safety and effectiveness in children below 18 years of age have not been established in randomized, controlled clinical trials. However, the use of warfarin sodium tablets in pediatric patients has been documented for the prevention and treatment of thromboembolic events.

Adequate and well-controlled studies with Warfarin Tablets have not been conducted in any pediatric population, and the optimum dosing, safety, and efficacy in pediatric patients is unknown. Pediatric use of Warfarin Tablets is based on adult data and recommendations, and available limited pediatric data from observational studies and patient registries. Pediatric patients administered Warfarin Tablets should avoid any activity or sport that may result in traumatic injury.

The developing hemostatic system in infants and children results in a changing physiology of thrombosis and response to anticoagulants. Dosing of warfarin in the pediatric population varies by patient age, with infants generally having the highest, and adolescents having the lowest milligram per kilogram dose requirements to maintain target INRs. Because of changing warfarin requirements due to age, concomitant medications, diet, and existing medical condition, target INR ranges may be difficult to achieve and maintain in pediatric patients, and more frequent INR determinations are recommended. Bleeding rates varied by patient population and clinical care center in pediatric observational studies and patient registries.

Infants and children receiving vitamin K–supplemented nutrition, including infant formulas, may be resistant to warfarin therapy, while human-milk–fed infants may be sensitive to warfarin therapy.

### 7.1.4 Geriatrics (≥ 60 years of age):

Patients 60 years or older appear to exhibit greater than expected PT/INR response to the anticoagulation effects of warfarin see [10.3 Pharmacokinetics, Special Populations and Conditions, Geriatrics](#). Warfarin sodium is contraindicated in any unsupervised patients with conditions associated with potential high level of noncompliance such as senility, alcoholism, or psychosis or other lack of patient cooperation. Caution should be exercised with administration of warfarin sodium to elderly and/or debilitated patients in any situation or physical condition where added risk of hemorrhage is present. Low initiation and maintenance doses of TARO-WARFARIN are

recommended in the elderly. See [4.2 Recommended Dose and Dosage Adjustment](#).

## 8 Adverse Reactions

### 8.1 Adverse Reaction Overview

Potential adverse reactions to TARO-WARFARIN (warfarin sodium) tablets may include:

#### Hemorrhage

Hemorrhage, ranging from minor to severe bleeding (including fatal outcomes), can occur during therapy with TARO-WARFARIN. Hemorrhage may occur in any tissue or organ, manifesting as external or internal bleeding with associated symptoms and complications. This is a consequence of the anticoagulant effect.

Typically, the following body systems may be affected:

- **upper (gingival bleeding, hematemesis) or lower (melena, hematochezia, rectal bleeding) gastrointestinal tract**
- **retroperitoneal space**
- **respiratory tract (epistaxis, hemoptysis), including rare cases of pulmonary alveolar hemorrhage**
- **genitourinary tract (hematuria, vaginal bleeding, menorrhagia)**
- **skin (contusion, ecchymosis, and petechia)**

Central nervous system hemorrhage, including intracranial hemorrhage or spinal hematoma, ocular, intra-articular, pleural, pericardial, adrenal, and hepatic hemorrhage may also occur.

Some hemorrhagic complications may present as signs and symptoms that are not immediately identified as resulting from hemorrhage.

The signs, and symptoms, and severity will vary according to the location and degree or extent of the bleeding. Haemorrhagic complications may present as paralysis, paresthesia, headache, chest, abdomen, joint, muscle or other pain; dizziness, shortness of breath, difficult breathing or swallowing, unexplained swelling, weakness, hypotension, anaemia, purple toe syndrome, fatigue, lethargy, malaise, pallor, syncope or unexplained shock. Therefore, the possibility of haemorrhage should be considered in evaluating the condition of any anticoagulated patients with complaints which do not indicate an obvious diagnosis. Bleeding during anticoagulant therapy does not always correlate with PT ratio/INR (see [5 Overdose](#)).

Bleeding which occurs when the PT ratio/INR is within the therapeutic range warrants diagnostic investigation, since it may unmask a previously unsuspected lesion, e.g. tumour, ulcer, etc.

**Necrosis of skin and other tissues** (see [7 Warnings and Precautions, Skin](#)).

**Systemic atheroemboli and cholesterol microemboli** (see [7 Warnings and Precautions, Cardiovascular](#))

### 8.5 Post-marketing Adverse reactions

The following adverse reactions have been reported from post-marketing experience with warfarin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.

**Blood and lymphatic system disorders:** anemia

Cases of atraumatic splenic rupture in patients taking warfarin have been reported.

**Cardiac disorders:** angina, chest pain, pericardial haemorrhage

**Endocrine disorders:** adrenal haemorrhage

**Eye disorders:** eye haemorrhage

**Gastrointestinal disorders:** abdominal pain including cramping, abdominal distention, diarrhea, dysgeusia, dysphagia, flatulence/bloating, gingival bleeding, haematemesis, haematochezia, maelena, nausea, rectal haemorrhage, retroperitoneal haemorrhage, taste perversion, vomiting

**General disorders and administration site conditions:** asthenia, fatigue, edema, swelling, feeling cold and chills, malaise, pain pallor, fever

**Hepatobiliary disorders:** hepatitis, hepatic haemorrhage, jaundice, cholestatic hepatic injury

**Immune system disorders:** anaphylactic reaction: hypersensitivity/allergic reactions **Monitoring**

**and Laboratory Tests:** hepatic enzyme increased

**Musculoskeletal, connective tissue and bone disorders:** arthralgia, haemarthrosis, myalgia

**Nervous system disorders:** dizziness, headache, haemorrhage intracranial, paraesthesia, paralysis, spinal haematoma, cold intolerance, coma, loss of consciousness,

**Psychiatric disorders:** lethargy

**Renal and urinary disorders:** haematuria, acute kidney injury, anticoagulant-related nephropathy (ARN)

**Reproductive system and breast disorders:** vaginal haemorrhage, menorrhagia

Priapism has been associated with anticoagulant administration; however, a causal relationship has not been established.

**Respiratory, thoracic and mediastinal disorders:** epistaxis, dyspnoea, haemoptysis, haemothorax, pulmonary alveolar haemorrhage, pulmonary calcification

Rare events of tracheal or tracheobronchial calcification have been reported in association with long-term warfarin therapy. The clinical significance of this event is unknown.

**Skin and subcutaneous tissue disorders:** ecchymosis, pruritus, rash, alopecia, dermatitis, petechia, urticaria, skin necrosis, dermatitis bullous calciphylaxis

**Vascular disorders:** haemorrhage, hypotension, syncope, vasculitis, shock, blue toe syndrome, embolism arterial, fat embolism, necrosis, systemic cholesterol microembolization,

## 9 Drug Interactions

### 9.2 Drug Interactions Overview

CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. The more potent warfarin S-enantiomer (60% of the overall anticoagulation response) is metabolized by CYP2C9 while the R-enantiomer is metabolized by CYP1A2 and 3A4. The steady state concentration of warfarin is mediated by CYP2C9 mediated metabolism of S-enantiomer.

- Inhibitors of CYP2C9, 1A2, and/or 3A4 have the potential to increase the effect (increase INR) of warfarin by increasing the exposure of warfarin.
- Inducers of CYP2C9, 1A2, and/or 3A4 have the potential to decrease the effect (decrease INR) of warfarin by decreasing the exposure of warfarin.

Acquired or inherited warfarin resistance should be suspected if large daily doses of TARO-WARFARIN Tablets are required to maintain a patient's PT ratio/INR within a normal therapeutic range.

Medications of unknown interaction with coumarins are best regarded with caution. When these medications are started or stopped, more frequent PT ratio/INR monitoring is advisable.

Coumarins may also affect the action of other drugs. Hypoglycaemic agents (chlorpropamide and tolbutamide) and anticonvulsants (phenytoin and phenobarbital) may accumulate in the body as a result of interference with either their metabolism or excretion.

It has been reported that concomitant administration of warfarin and ticlopidine may be associated with cholestatic hepatitis.

### 9.4 Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

**Table 2 - Established or Potential Drug-Drug Interactions**

Non-proprietary names of the drug products	Source of Evidence	Effect	Clinical comment
Antibiotics and antifungals	CT	May change international normalized ratio (INR).	There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown consistent effects of these agents on plasma concentrations of warfarin. Coadministration with warfarin should be avoided or closely monitor INR when starting or stopping any antibiotic or antifungal in patients taking TARO-WARFARIN.
Anticoagulants  Platelet antiaggregants  Thrombolytics  Serotonin reuptake inhibitors	CT  CT  C  CT	May increase bleeding risk.	Bleeding risk is increased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such class of drug with TARO-WARFARIN. Adjust dosage accordingly or discontinue if necessary.
Nonsteroidal anti-inflammatory drugs (NSAIDs)	C, CT	May affect prothrombin time. May inhibit platelet aggregation. May cause gastrointestinal bleeding, peptic ulceration and/or perforation. May increase bleeding risk.	Close monitoring of patients receiving nonsteroidal anti-inflammatory agents (NSAIDs) is recommended to be certain that no change in anticoagulation dosage is required. Bleeding risk is increased when these drugs are used concomitantly with warfarin. Adjust dosage accordingly or discontinue if necessary. Consult the labeling of all concurrently used drugs to obtain further information about interactions with TARO-WARFARIN or adverse reactions pertaining to bleeding.

Legend: C = Case Study; CT = Clinical Trial

**The following factors, alone or in combination, may be responsible for INCREASED PT ratio or INR, or INCREASED risk of bleeding:**

**Table 3. ENDOGENOUS FACTORS that may be Responsible for Increased PT ratio or INR:**

blood dyscrasias	diarrhea	Hyperthyroidism
Cancer	elevated temperature	poor nutritional state
collagen vascular disease	hepatic disorders (infectious hepatitis, jaundice)	Steatorrhea
congestive heart failure		vitamin K deficiency

**EXOGENOUS FACTORS:**

Potential drug interactions with TARO-WARFARIN are listed below by drug class and by specific drugs.

**Table 4. Classes of Drugs that may Interact with TARO-WARFARIN and be Responsible for Increased PT ratio or INR**

5-lipoxygenase Inhibitors	Adrenergic Stimulants, Central Alcohol Abuse Reduction Preparations	Analgesics
Anaesthetics, Inhalation	Antiandrogens	Antiarrhythmics *
Antibiotics * Aminoglycosides (oral) Cephalosporins (parenteral) Macrolides Penicillins (intravenous), high dose Quinolones (fluoroquinolones) Sulfonamides (long acting) Tetracyclines	Anticoagulants	Anticonvulsants *
Antidepressants *	Anti-fungal Medications, Intravaginal, Systemic*	Antimalarial Agents
Antineoplastics*	Antiparasitic/Antimicrobials	Antiplatelet Drugs/Effects
Antithyroid Drugs *	Beta-Adrenergic Blockers	Cholelitholytic Agents
Diabetes Agents, Oral Diuretics *	Gastric Acidity and Peptic Ulcer Agents *	Gastrointestinal, Ulcerative Colitis Agents
Gastrointestinal, Prokinetic Agents	Gout Treatment Agents	Hemorrhologic Agents
Hepatotoxic Drugs	Hyperglycemic Agents	Hypertensive Emergency Agents

Hypnotics *	Leukotriene Receptor Antagonists	Lipid Lowering Agents* Bile Acid-Binding Resins* Fibrates HMG-CoA Reductase Inhibitors*
Monoamine Oxidase Inhibitors	Narcotics, prolonged	Natural medicines
Nonsteroidal Anti-Inflammatory Agents (COX-2 Inhibitors, Nonselective NSAIDS)	Psychostimulants	Pyrazolones
Salicylates	Selective Serotonin Reuptake Inhibitors	Steroids, Adrenocortical *
Steroids, Anabolic (17-Alkyl Testosterone Derivatives)	Thrombolytics	Thyroid Drugs
Tuberculosis Agents *	Uricosuric Agents	Vaccines
Vitamins *		

**Table 5. Specific Drugs that may Interact with TARO-WARFARIN and be Responsible for Increased PT ratio or INR**

Acetaminophen (paracetamol)	alcohol*	allopurinol	aminosalicylic acid	amiodarone HCl
amoxicillin	argatroban	ASA (acetylsalicylic acid)	azithromycin	bezafibrate
Benzbromarone	benziodarone	bivalirudin	capecitabine	carboplatin
cefaclor	cefamandole	cefazolin	cefixime	cefonicid
cefoperazone	cefotetan	cefotiam	cefoxitin	ceftriaxone
cefuroxime	celecoxib	chenodiol	chloramphenicol	chloral hydrate*
chlorpropamide	cholestyramine*	cimetidine	ciprofibrate	ciprofloxacin
cisapride	citalopram	clarithromycin	clofibrate	cyclophosphamide*
danazol	danshen (Chinese herb)	desirudin	dextran	dextrothyroxine
diazoxide	diclofenac	dicumarol	diflunisal	disulfiram
doxycycline	econazole	erythromycin	escitalopram	esomeprazole
ethacrynic acid	ezetimibe	fenofibrate	fenoprofen	fluconazole
fluorouracil	fluoxetine	flutamide	fluvastatin	fluvoxamine
gatifloxacin	gefitinib	gemfibrozil	glucagon	glucosamine
halothane	heparin	ibuprofen	ifosfamide	indomethacin
influenza virus vaccine	itraconazole	ketoconazole	ketoprofen	ketorolac
lansoprazole	leflunomide	lepirudin	levamisole	levofloxacin
levothyroxine	liothyronine	lovastatin	medroxyproges	mefenamic acid

			terone	
megestrol	memantine	metandienone	methimazole*	methyldopa
Methyl prednisolone	methylphenidate	Methylsalicylate ointment (topical)	metronidazole	miconazole (intravaginal, oral, systemic*)
moricizine hydrochloride*	moxifloxacin	nalidixic acid	naproxen	neomycin
norfloxacin	noscapine	ofloxacin	olsalazine	omeprazole
orlistat	oxandrolone	oxaprozin	Oxolamine	oxymetholone
paclitaxel	pantoprazole	paroxetine	penicillin G, intravenous	pentoxifylline
phenylbutazone	phenytoin*	piperacillin	piroxicam	prasugrel
pravastatin	prednisone*	propafenone	propoxyphene	propranolol
propylthiouracil*	quinidine	quinine	rabeprazole	ranitidine*
rofecoxib	roxithromycin	sertraline	simvastatin	stanozolol
streptokinase	sulfamethizole	sulfamethoxazole	sulfinpyrazone	sulfisoxazole
sulindac	tamoxifen	tegafur	telithromycin	tetracycline
thyroid	ticarcillin	Tienilic acid	ticlopidine	tissue plasminogen activator (t-PA)
tolbutamide	tolterodine	toremifene	tramadol	trimethoprim /sulfamethoxazole
urokinase	valproate	vitamin E	voriconazole	zafirlukast
also: other medications affecting blood elements which may modify hemostasis dietary deficiencies; prolonged hot weather; unreliable PT determinations * Increased and decreased PT ratio/INR responses have been reported.				

**The following factors, alone or in combination, may be responsible for DECREASED PT ratio or INR, or increased potential risk of thromboembolic events:**

**Table 6. ENDOGENOUS FACTORS that may be Responsible for Decreased PT ratio or INR**

edema	hyperlipemia
hereditary coumarin resistance	hypothyroidism
	nephrotic syndrome

EXOGENOUS FACTORS

**Potential drug interactions with TARO-WARFARIN are listed below by drug class and by specific drugs**

**Table 7. Classes of Drugs that may Interact with TARO-WARFARIN and be Responsible for Decreased PT ratio or INR**

Adrenal Cortical Steroid Inhibitors	Antacids	Antianxiety Agents
Antiarrhythmics*	Antibiotics*	Anticonvulsants*
Antidepressants*	Anti-fungal Medications, Systemic*	Antihistamines
Antineoplastics*	Antipsychotic Medications	Antithyroid Drugs*
Barbiturates	Diuretics*	Enteral Nutritional Supplements
Enzyme inhibitors	Gastric Acidity and Peptic Ulcer Agents*	Hypnotics*
Immunosuppressives	Lipid Lowering Agents Bile Acid-Binding Resins* HMG-CoA Reductase Inhibitors*	Natural medicines
Oral Contraceptives, Estrogen Containing Selective Estrogen Receptor Modulators Steroids, Adrenocortical*	Tuberculosis Agents*	Vitamins*

**Table 8. Specific Drugs Reported to Interact with TARO-WARFARIN and be Responsible for Decreased PT ratio or INR**

alcohol*	aminoglutethimide	amobarbital
aprepitant	atorvastatin	azathioprine
bosentan	butabarbital	butalbital
carbamazepine	chloral hydrate*	chlordiazepoxide
chlorthalidone	cholestyramine*	corticotropin
cortisone	Warfarin sodium underdose	cyclophosphamide*
dicloxacillin	ethchlorvynol	fosaprepitant
glutethimide	griseofulvin	haloperidol
meprobamate	6-mercaptopurine	methimazole*
moricizine hydrochloride*	nafcillin	paraldehyde
pentobarbital	phenobarbital	phenytoin*
prednisone*	primidone	propylthiouracil*
raloxifene	rifampin	rifapentine
ranitidine*	secobarbital	spironolactone
sucralfate	trazodone	vitamin C (high dose)

vitamin K		
also: diet high in vitamin K; unreliable PT determinations		
* Increased and decreased PT ratio/INR responses have been reported.		

## 9.5 Drug-Food Interactions

Some foods (eg, certain green vegetables such as broccoli which are rich in vitamin K) can interact with TARO-WARFARIN. Other foods may interact with TARO-WARFARIN through CYP450 interactions (eg, grapefruit juice).

Cranberry juice and other cranberry products may also interact with TARO-WARFARIN.

## 9.6 Drug-Herb Interactions

### Natural Medicines (Including Herbals and Botanicals)

**Caution should be exercised when natural medicines are taken concomitantly with TARO-WARFARIN Tablets.** Few, adequate, well-controlled studies exist evaluating the potential for metabolic and/or pharmacologic interactions between natural medicines and warfarin sodium. Due to a lack of manufacturing standardization with natural medicines, the amount of active ingredients may vary. This could further confound the ability to assess potential interactions and effects on anticoagulants.

It is good practice to monitor the patient's response with additional PT/INR determinations when initiating or discontinuing natural medicines.

Specific natural medicines reported to affect the Warfarin Sodium tablets therapy include the following:

- Bromelains, danshen, dong quai (*Angelica sinensis*), garlic, and Ginkgo biloba, ginseng, and cranberry products are associated most often with an INCREASE in the effects of Warfarin Sodium tablets. However, the effects of ginseng can be variable (increased or decreased effect of Warfarin Sodium tablets) and the combination should be avoided or more careful monitoring is warranted.
- **Coenzyme Q<sub>10</sub> (ubidecarenone) and St. John's wort are associated most often with a DECREASE in the effects of Warfarin Sodium tablets.**
- Echinacea has also been reported to interact with warfarin sodium.

Some natural medicines may cause bleeding events when taken alone (e.g., garlic and Ginkgo biloba) and may have anticoagulant, antiplatelet, and/or fibrinolytic properties. These effects would be expected to be additive to the anticoagulant effects of Warfarin Sodium tablets. Conversely, other natural medicines may have coagulant properties when taken alone or may decrease the effects of Warfarin Sodium tablets.

Some natural medicines that may affect coagulation are listed below for reference; however,

this list should not be considered all-inclusive. Many natural medicines have several common names and scientific names. The most widely recognized common natural medicines names are listed.

**Table 9. Natural medicines that contain coumarins with potential anticoagulant effects:**

Agrimony <sup>a</sup> ( <i>Argimonia eupatoria</i> )	Licorice <sup>d</sup> ( <i>Glycyrrhiza globra</i> )
Alfalfa ( <i>Medicago sativa</i> )	Meadowsweet <sup>b</sup> ( <i>Spiræa ulmaria</i> )
Aniseed ( <i>Pimpinella anisum</i> )	Nettle ( <i>Urtica dioica</i> )
Arnica	Parsley ( <i>Carum petroselinum</i> )
Asa Foetida ( <i>Asafetida</i> )	Passion Flower ( <i>Passiflora edulis</i> )
Bogbean <sup>b</sup> ( <i>Menyanthis folium</i> )	Prickley Ash - Northern ( <i>Zanthoxylum americanum</i> )
<i>Peumus Boldo</i>	Quassia ( <i>Amara</i> )
Buchu ( <i>Barosmae boldo</i> )	Red Clover ( <i>Trifoliumpratense</i> )
Paprika ( <i>Capsicum</i> )	Sweet Clover ( <i>Melilotus officinalis</i> )
Cassia <sup>c</sup>	Sweet Woodruff ( <i>Galii odorati herba</i> )
Celery ( <i>Apium graveolens</i> )	Tonka Beans ( <i>Dipteryx odorata</i> )
Chamomile - German and Roman ( <i>Anthemis nobilis</i> )	Wild Carrot ( <i>Daucus carota</i> ) Wild Lettuce ( <i>Lactuca virosa</i> )
Dandelion <sup>c</sup> ( <i>Taraxacum officinale</i> )	Dong Quai ( <i>Angelica sinensis</i> )
Fenugreek ( <i>Trigonella fœnumgræcum</i> )	Horse Chestnut ( <i>Æsculus hippocastanum</i> )
Horseradish ( <i>Cochleria armoracia</i> )	

**Miscellaneous natural medicines with anticoagulant properties:**

Bladder Wrack (*Fucus vesiculosus*)                      Pau d'arco (*Tabebuia avellanedæ*)

**Table 10. Natural medicines that contain salicylate and/or have antiplatelet properties:**

Agrimony <sup>a</sup>	Ginger
Aloe Gel	Ginko Biloba
Aspen ( <i>Populus tremuloides</i> )	Ginseng ( <i>Panax spp</i> ) <sup>e</sup>
Black Cohosh ( <i>Cimicifuga racemosa</i> )	Licorice <sup>c</sup>
Black Haw ( <i>Viburnum prunifolium</i> )	Meadowsweet <sup>b</sup>
Bogbean <sup>b</sup>	Onion <sup>e</sup> ( <i>Allium cepa</i> )
Cassia <sup>d</sup>	Policosanol
Clove ( <i>Eugenia caryophyllus</i> )	Poplar ( <i>Populi gemma</i> )
Cranberry	Senega ( <i>Polygala</i> )
Dandelion <sup>d</sup>	Tamarind ( <i>Tamarindus Indica</i> )
Feverfew ( <i>Chrysanthemum parthenum</i> )	Willow ( <i>Salix nigra</i> )
Garlic <sup>e</sup> ( <i>Tremuloides</i> )	Wintergreen ( <i>Gaultheria procumbens</i> )

German Sarsaparilla ( <i>Corex arenaria</i> )	
---	--

**Table 11. Natural medicines with fibrinolytic properties:**

Bromelains ( <i>Bromelainum</i> )	Ginseng ( <i>Panax spp</i> ) <sup>e</sup>
Capsicum <sup>c</sup>	Inositol Nicotinate
Garlic <sup>e</sup>	Onion <sup>e</sup>

**Table 12. Natural medicines with coagulant properties:**

Green vegetables	Goldenseal ( <i>Chrysanthemum</i> )
Mistletoe ( <i>Viscum album</i> )	St John's wort ( <i>hypericum perforatum</i> )
Yarrow ( <i>Achillea millefolium</i> )	

- a. Contains coumarins, has antiplatelet properties, and may have coagulant properties due to possible vitamin K content.
- b. Contains coumarins and salicylate.
- c. Contains coumarins and has fibrinolytic properties.
- d. Contains coumarins and has antiplatelet properties.
- e. Has antiplatelet and fibrinolytic properties.

## 9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

## 10 Clinical Pharmacology

### 10.1 Mechanism of Action

Warfarin sodium and other coumarin anticoagulants act by inhibiting the synthesis of Vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. Half-lives of these clotting factors are as follows: Factor II - 60 hours, VII - 4-6 hours, IX - 24 hours, and X - 48-72 hours. The half-lives of proteins C and S are approximately 8 hours and 30 hours, respectively. The resultant *in vivo* effect is a sequential depression of Factors VII, IX, X and II. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of  $\gamma$ -carboxyglutamic acid residues in the proteins which are essential for biological activity. Warfarin is thought to interfere with clotting factor synthesis by inhibition of the regeneration of vitamin K<sub>1</sub> epoxide. The degree of depression is dependent upon the dosage administered. Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.

### 10.2 Pharmacodynamics

An anticoagulation effect generally occurs within 24 hours after drug administration. However, peak anticoagulant effect may be delayed 72 to 96 hours. The duration of action of a single dose of racemic warfarin is 2 to 5 days. The effects of warfarin may become more pronounced as effects of daily maintenance doses overlap. Anticoagulants have no direct effect on an established

thrombus, nor do they reverse ischemic tissue damage. However, once a thrombus has occurred, the goal of anticoagulant treatment is to prevent further extension of the formed clot and prevent secondary thromboembolic complications which may result in serious and possibly fatal sequelae.

### 10.3 Pharmacokinetics

Taro-WARFARIN is a racemic mixture of the R- and S-enantiomers. The S-enantiomer exhibits 2-5 times more anticoagulant activity than the R-enantiomer in humans, but generally has a more rapid clearance. It is important that all warfarin sodium products provide the same ratio of enantiomers as that which is present in TARO-WARFARIN tablets.

#### Absorption

Warfarin is essentially completely absorbed after oral administration with peak concentration generally attained within the first 4 hours. Studies using warfarin sodium indicate the rate but not the extent of absorption of the drug is decreased by the presence of food in the GI tract. Warfarin is also absorbed percutaneously. Individuals differ in the rate at which they absorb warfarin.

#### Distribution

There are no differences in the apparent volumes of distribution after intravenous and oral administration of single doses of warfarin solution. Warfarin distributes into a relatively small apparent volume of distribution of about 0.14 litre/kg. A distribution phase lasting 6 to 12 hours is distinguishable after rapid intravenous or oral administration of an aqueous solution. Using a one compartment model, and assuming complete bioavailability, estimates of the volumes of distribution of R- and S-warfarin are similar to each other and to that of the racemate. Warfarin is distributed to the liver, lungs, spleen, kidney, and crosses the placenta. Concentrations in fetal plasma approach the maternal values, but warfarin has not been found in human milk (see [7.1.2 Breastfeeding](#)). Approximately 99% of the drug is bound to plasma proteins.

#### Metabolism

Individual patients vary greatly in the rate at which they metabolize warfarin. The elimination of warfarin is almost entirely by metabolism. Warfarin Sodium is stereoselectively metabolized by hepatic microsomal enzymes (cytochrome P-450) to inactive hydroxylated metabolites (predominant route) and by reductases to reduced metabolites (warfarin alcohols). The warfarin alcohols have minimal anticoagulant activity. The metabolites are principally excreted into the urine; and to a lesser extent into the bile. The metabolites of warfarin that have been identified include dehydrowarfarin, two diastereoisomer alcohols, 4'-, 6-, 7-, 8- and 10-hydroxywarfarin.

Numerous cytochrome p-450 isozymes may be involved in the metabolism of warfarin, including CYP 2C9, 2C19, 2C8, 2C18, 1A2 and 3A4. CYP 2C9 is likely to be the principal isozyme modulating anticoagulant activity in clinical use. This enzyme constitutes the primary pathway for the metabolism of S-warfarin, the more potent enantiomer found in racemic mixtures of warfarin. Its

complete inhibition *in vivo* may be expected to result in lower maintenance dose requirement of warfarin. Individuals with allelic polymorphisms of CYP 2C9 have been identified and have been shown to have lower maintenance dose requirements of warfarin and increased risk of overanticoagulation.

The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme. The variant alleles CYP2C9\*2 and CYP2C9\*3 result in decreased *in vitro* CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9\*2 and CYP2C9\*3, respectively. Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance (Table 13).

**Table 13. Relationship between S-Warfarin Clearance and CYP2C9 Genotype in Caucasian Patients**

CYP2C9 Genotype	N	S-Warfarin Clearance/Lean Body Weight (mL/min/kg) Mean (SD) <sup>a</sup>
*1/*1	118	0.065 (0.025) <sup>b</sup>
*1/*2 or *1/*3	59	0.041 (0.021) <sup>b</sup>
*2/*2, *2/*3 or *3/*3	11	0.020 (0.011) <sup>b</sup>
Total	188	

<sup>a</sup>SD=standard deviation.

<sup>b</sup>p<0.001. Pairwise comparisons indicated significant differences among all 3 genotypes.

Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including \*5, \*6, and \*11 alleles in populations of African ancestry and \*5, \*9 and \*11 alleles in Caucasians.

### Elimination

The terminal half-life of warfarin after a single dose is approximately one week; however, the effective half-life ranges from 20 to 60 hours, with a mean of about 40 hours. The clearance of R-warfarin is generally half that of S-warfarin, thus as the volumes of distribution are similar, the half-life of R-warfarin is longer than that of S-warfarin. The half-life of R-warfarin ranges from 37 to 89 hours, while that of S-warfarin ranges from 21 to 43 hours. Studies with radiolabeled drug have demonstrated that up to 92% of the orally administered dose is recovered in urine. Very little warfarin is excreted unchanged in urine. Urinary excretion is in the form of metabolites.

### **Special Populations and Conditions:**

- **Geriatrics:** Patients 60 years or older appear to exhibit greater than expected PT/INR response to the anticoagulation effects of warfarin. The cause of this increased sensitivity in this age group is not known. This increased anticoagulant effect of warfarin may be due to a combination of pharmacokinetic and pharmacodynamic factors. Racemic warfarin clearance may be unchanged or reduced with increasing age. Limited information suggest that there is

no difference in the clearance of S-warfarin in the elderly, compared to that seen in young subjects. However, there may be a slight decrease in the clearance of R-warfarin in the elderly, compared to the young. Therefore, as patient age increases, a lower dose of warfarin is usually required to produce a therapeutic level of anticoagulation.

- **Genetic Polymorphism:** A meta-analysis of 9 qualified studies including 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients. In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9\*2 or CYP2C9\*3 alleles. Patients carrying at least one copy of the CYP2C9\*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9\*1 allele. For patients carrying at least one copy of the CYP2C9\*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9\*1 allele.

In an observational study, the risk of achieving INR >3 during the first 3 weeks of warfarin therapy was determined in 219 Swedish patients retrospectively grouped by CYP2C9 genotype. The relative risk of over anticoagulation as measured by INR >3 during the first 2 weeks of therapy was approximately doubled for those patients classified as \*2 or \*3 compared to patients who were homozygous for the \*1 allele.

Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle, through inhibition of vitamin K epoxide reductase (VKOR), a multiprotein enzyme complex.

Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G>A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined. About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients. Similar observations have been reported in Asian patients.

- **Hepatic Impairment:** Hepatic dysfunction can potentiate the response to warfarin through impaired synthesis of clotting factors and decreased metabolism of warfarin.
- **Renal Impairment:** Renal clearance is considered to be a minor determinant of anticoagulant response to warfarin.

## 11 Storage, Stability, and Disposal

Protect from light. Store at controlled room temperature (15 °C to 30 °C). Dispense in a tight, light-resistant container as defined in the USP.

## 12 Special Handling Instructions

Warfarin is absorbed percutaneously.

Pharmacy and clinical personnel who are pregnant should avoid exposure to crushed or broken tablets (see [7 Warnings and Precautions](#), [7.1.1 Pregnancy](#)).


**PART II: SCIENTIFIC INFORMATION****13 Pharmaceutical Information****Drug Substance:**

Non-proprietary name of the drug substance: Warfarin sodium, U.S.P.

Chemical Name: 3-(a-acetyl-benzyl)-4-hydroxycoumarin sodium salt isopropanol clathrate

Molecular formula and molecular mass:  $C_{19}H_{15}NaO_4 \cdot \frac{1}{2} C_3H_8O$  and (330.31 + 30.05)

Structural Formula:



Physicochemical properties:

Description:

Warfarin sodium, U.S.P., a Vitamin K dependent factor anticoagulant, is chemically crystalline sodium warfarin isopropanol clathrate. Warfarin is a coumarin derivative and is available as a racemic mixture of the 2 optical isomers of the sodium salt. The crystallization of warfarin sodium virtually eliminates trace impurities present in amorphous warfarin sodium, thus achieving a crystalline product of the highest purity. Warfarin sodium occurs as a white, odourless, crystalline powder which has a slightly bitter taste, is discoloured by light and is very soluble in water, freely soluble in alcohol; very slightly soluble in chloroform and in ether. The pH is between 7.2 and 8.3, in a solution (1 in 100). The melting point of the free acid is between 157°C - 167° C, range not to exceed 4 °C. The pKa is 5.05.

**14 Clinical Trials****14.1 Clinical Trial by Indication**

No information on clinical trials is available.

**14.2 Comparative Bioavailability Studies**

Bioavailability studies were performed in order to establish bioequivalence between TARO-

WARFARIN tablets and the brand product. The results of the studies are summarized in the tables below:

A Two-way, Crossover, Single 10 mg Dose, Food-Effect & Fasting comparative bioavailability Study of TARO-WARFARIN (Warfarin Sodium) Immediate Release Tablets USP, 10 mg Tablets (Taro Pharmaceuticals Inc.) and COUMADIN® 10 mg Tablets (DuPont Pharma, Canada) was conducted. A summary of the bioavailability study is presented in the following two tables:

**Table 14- SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA (10 mg tablet -Food-Effect)**

Warfarin Sodium Tablets (1 x 10 mg) 10 mg				
Geometric Mean Arithmetic Mean (CV %)				
PARAMETER	Test <sup>1</sup>	Reference <sup>2</sup>	Ratio of Geometric Means	95% Confidence Interval (80 - 125%)
AUC <sub>0-72</sub> (ng hr/mL)	37681	36783	102	(98-107)
	37672 (15%)	37252 (13%)		
AUC <sub>0-T</sub> (ng hr/mL)	46187	45075	102	(98-108)
	46241 (17%)	45761 (14%)		
AUC <sub>0-inf</sub> (ng hr/mL)	52257	51166	102	(97-108)
	52396 (18%)	52153 (16%)		
C <sub>max</sub> (ng/mL)	1099	1098	100	(95-105)
	1097 (14%)	1105 (10%)		
T <sub>max</sub> (hr) <sup>3</sup>	3.14 (44%)	3.32 (41%)		
T <sub>1/2</sub> (hr) <sup>3</sup>	38.4 (15%)	39.4 (13%)		

1 TARO-WARFARIN (Warfarin Sodium) Tablets USP, 10 mg Tablets (Taro Pharmaceuticals Inc.)

2 COUMADIN® 10 mg Tablets (DuPont Pharma, Canada)

3 for T<sub>max</sub> and T<sub>1/2</sub> arithmetic mean (CV%) are presented

\*Purchased in Canada

**Table 15- SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA (10 mg tablet -Fasting)**

Warfarin Sodium Tablets (1 x 10 mg)				
Geometric Mean				
Arithmetic Mean (CV %)				
PARAMETER	Test <sup>1</sup>	Reference <sup>2</sup>	Ratio of Geometric Means	95% Confidence Interval (80 - 125%)
AUC <sub>0-72</sub> (ng hr/mL)	38280	38226	100	96-104
	39699 (21%)	39649 (19%)		
AUC <sub>0-t</sub> (ng-hr/mL)	47345	47038	101	97 - 105
	49260 (26%)	48854 (20%)		
AUC <sub>0-inf</sub> (ng-hr/mL)	55467	54870	101	96 - 106
	59145 (41%)	57558 (26%)		
C <sub>max</sub> (ng/mL)	1324	1416	94	87 - 100
	1387 (17%)	1481(20%)		
T <sub>max</sub> (hr) <sup>3</sup>	1.78 (186 %)	1.17 (88%)	-----	
T <sub>1/2</sub> (hr) <sup>3</sup>	44.0 (28%)	43.8 (23%)	-----	

1 TARO-WARFARIN (Warfarin Sodium) Tablets USP, 10 mg Tablets (Taro Pharmaceuticals Inc.)

2 COUMADIN® 10 mg Tablets (DuPont Pharma, Canada)

3 for T<sub>max</sub> and T<sub>1/2</sub> arithmetic mean (CV%) are presented

\*Purchased in Canada

A Two-way, Crossover, Single 1 mg Dose, Fasting and Fed comparative bioavailability Study of TARO-WARFARIN (Warfarin Sodium) Immediate Release Tablets USP, 10 mg Tablets (Taro Pharmaceuticals Inc.) and COUMADIN® 10 mg Tablets (DuPont Pharma, Canada) was conducted. A summary of the bioavailability study is presented in the following two tables:

**Table 16- SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA (1 mg tablet -Fasting)**

Warfarin Sodium Tablets (2 x 1 mg)				
Geometric Mean				
Arithmetic Mean (CV %)				
PARAMETER	Test <sup>1</sup>	Reference <sup>2</sup>	% RATIO OF MEANS	95% Confidence Interval (80-125%)
AUC <sub>0-72h</sub> (ng.hr/mL)	4716.72 4876.27 (24.33%)	4563.34 4667.06 (21.50%)	103.36	96.29 - 110.96
AUC <sub>0-inf</sub> (ng.hr/mL)	8305.53 8773.99 (32.83%)	8234.22 8504.53 (27.34%)	100.87	91.76 - 110.88
C <sub>max</sub> (ng/mL)	234.9 240.19 (20.71%)	239.21 244.99 (24.20%)	98.19	90.48 - 106.56
T <sub>max</sub> (hr) <sup>3</sup>	0.548 (23.36%)	0.667 (104.28%)	-----	
T <sub>1/2 el</sub> (hr) <sup>3</sup>	63.29 (25.86%)	64.27 (27.92%)	-----	

1 TARO-WARFARIN (Warfarin Sodium) Tablets USP, 1 mg Tablets (Taro Pharmaceuticals Inc.)

2 COUMADIN® 1 mg Tablets (DuPont Pharma, Canada)

3 for T<sub>max</sub> and T<sub>1/2</sub> arithmetic mean (CV%) are presented

\*Purchased in Canada

**Table 17- SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA (1 mg tablet -Fed study)**

Warfarin Sodium Tablets (2 x 1 mg)				
Geometric Mean				
Arithmetic Mean (CV %)				
PARAMETER	Test <sup>1</sup>	Reference <sup>2</sup>	% RATIO OF MEANS	95% Confidence Interval (80-125%)
AUC <sub>0-72h</sub> (ng.hr/mL)	4691.52 4895.45 (29.03%)	4731.91 5012.25 (25.46%)	99.15	95.70 - 102.72
AUC <sub>0-inf</sub> (ng.hr/mL)	9234.38 9677.56 (34.18%)	8933.19 9500.91 (31.56%)	103.37	95.10 - 112.37
C <sub>max</sub> (ng/mL)	141.45 143.99 (20.34%)	146.68 151.73 (22.69%)	96.43	89.37 - 104.05
T <sub>MAX</sub> * (hr) <sup>3</sup>	2.47 (57.29%)	2.35 (55.53%)	-----	
T <sub>1/2 el</sub> * (hr) <sup>3</sup>	71.85 (25.95%)	67.16 (25.30%)	-----	

1 TARO-WARFARIN (Warfarin Sodium) Tablets USP, 1 mg Tablets (Taro Pharmaceuticals Inc.)

2 COUMADIN® 1 mg Tablets (DuPont Pharma, Canada)

3 for T<sub>max</sub> and T<sub>1/2</sub> arithmetic mean (CV%) are presented

\*Purchased in Canada

**15 Microbiology**

No microbiological information is required for this drug product.

**16 Non-Clinical Toxicology**

Carcinogenicity and mutagenicity studies have not been performed with warfarin sodium. The reproductive effects of warfarin have not been evaluated.

Warfarin is contraindicated in women who are or who may become pregnant because the drug passes through the placental barrier and may cause fatal haemorrhage to the fetus in *utero*. Furthermore, there have been reports of birth malformations in children born to mothers who have been treated with warfarin during pregnancy (see [2 Contraindications and 7.1.1 Pregnancy](#)).

**17 Supporting Product Monograph**

Coumadin® Product Monograph, Bristol-Myers Squibb Canada, submission control #217553,  
Date of Revision: September 4, 2018.

**PATIENT MEDICATION INFORMATION**

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

**Pr** TARO-WARFARIN**Warfarin Sodium Tablets**

This Patient Medication Information is written for the person who will be taking TARO-WARFARIN. This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This Patient Medication Information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about TARO-WARFARIN talk to a healthcare professional.

**Serious warnings and precautions box****Risk of bleeding:**

The most common side effect of TARO-WARFARIN is bleeding. The bleeding may be serious and life-threatening. You may be more at risk for bleeding if you have:

- a history of bleeding in your stomach or intestines (ulcers)
- high blood pressure
- heart disease
- problems with the blood circulation in your brain
- anemia (**decreased number of red blood cells**)
- cancer
- kidney disease
- experienced trauma or injury to your body.

Talk to your healthcare professional if you have any of the above conditions. You may also have a higher risk of bleeding if you take TARO-WARFARIN for a long time or if you take TARO-WARFARIN with certain other drugs. An INR level of 4.0 or greater is also a risk for bleeding. INR is a blood test that tells the level of blood clotting you have. Your healthcare professional will work to keep your INR within a range that is right for you. This will help lower the risk of bleeding. Notify your healthcare professional right away of any unusual bleeding or if signs or symptoms of bleeding occur (see “**What are possible side effects from using TARO-WARFARIN?**”) and the **Serious side effects and what to do about them table, below, for more information on this and other serious side effects.**”).

**What TARO-WARFARIN is used for:**

This medicine is used in adults. It helps prevent and treat blood clots:

- in the veins (venous thrombosis)
- in an artery in the lungs (pulmonary embolism)
- caused by irregular heartbeat (atrial fibrillation) with clots that dislodge and travel through the bloodstream (embolization)

It can also be used as an add-on treatment to prevent:

- blood clots after a heart attack (myocardial infarction), which could lead to a stroke or another heart attack
- mini-strokes (transient cerebral ischemic attacks) caused by abnormal blood clotting inside blood vessels.

#### **How TARO-WARFARIN works:**

TARO-WARFARIN partially blocks the re-use of vitamin K in your liver. Vitamin K is needed to make clotting factors. The clotting factors help the blood to clot and prevent bleeding. Vitamin K is found naturally in foods such as leafy, green vegetables and certain vegetable oils.

- TARO-WARFARIN begins to reduce blood clotting within 24 hours after taking the drug. The full effect may take 72 to 96 hours to occur. The anti-clotting effects of a single dose of TARO-WARFARIN last 2 to 5 days, but it is important for you to take your dose every day.

#### **The ingredients in TARO-WARFARIN are:**

Medicinal ingredient: warfarin sodium

Non-medicinal ingredients: magnesium stearate, lactose anhydrous, pregelatinized corn starch and colour dye which varies in each tablet strength:

- 1 mg: Pink color - D&C Red #6 - Lake
- 2 mg: Lavender - FD&C Blue #2 - Lake and FD&C Red #40 - Lake
- 2.5 mg: Green - FD&C Blue #2 - Lake and D&C Yellow #10 - Lake
- 3 mg: Tan - FD&C Red #40 - Lake, D&C Yellow #10 - Lake and FD&C Blue #2 -Lake
- 4 mg: Blue - FD&C Blue # 1- Lake
- 5 mg: Peach - D&C Yellow #10 - Lake and D&C Red #6 - Lake
- 6 mg: Teal - D&C Yellow #10 - Lake and FD&C Blue #2 - Lake
- 7.5 mg: Yellow - D&C Yellow #10 - Lake 10 mg: White - Dye free

#### **TARO-WARFARIN comes in the following dosage forms:**

TARO-WARFARIN tablets are available in 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5, and 10 mg strengths.

Each round, single-scored tablet is imprinted on one side with the word “WARFARIN” and the numeric strength of the tablet. The other side of the tablet is imprinted with the name “TARO”.

Be sure to check that the tablet shows “WARFARIN” and the right numeric strength before you

take it.

**Do not use TARO-WARFARIN if:**

- you are allergic to warfarin or any of the other ingredients in TARO-WARFARIN (see **The ingredients in TARO-WARFARIN are:**)
- you are pregnant, in particular if you have a high-risk pregnancy. Women who are able to get pregnant must use effective birth control to avoid pregnancy while taking TARO-WARFARIN. This is very important because your unborn baby could be seriously harmed if you take TARO-WARFARIN while you are pregnant. Your baby could be born with birth defects or could die.
- you are prone to bleeding due to problems with blood clotting, have low levels of platelets in your blood (thrombocytopenia) or have a deficiency of clotting proteins.
- you have recently had or are planning to have surgery of the eyes, central nervous system, or any major surgery.
- you have certain conditions such as:
  - stomach or intestinal bleeding or ulcers
  - bleeding in the lungs or kidneys, bladder or urethra
  - cerebral hemorrhage (bleeding in the brain)
  - heart infection
  - swelling of the heart membrane or fluid in the heart
  - a brain aneurysm (swelling of an artery that supplies blood to the brain).
- you recently had or are planning to have any medical procedure that can increase the risk of bleeding, such as spinal puncture or spinal anesthesia.
- you have severe uncontrolled high blood pressure.
- you consume alcohol or suffer from alcohol abuse.
- you practice any activity or sport that may result in serious injury.
- you have psychosis (a mental health problem).
- have memory problems, or any other condition that makes understanding and following instructions difficult.

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take TARO-WARFARIN. Talk about any health conditions or problems you may have, including if you:**

- fall often
- have liver or kidney problems or a heart problem called congestive heart failure
- have high blood pressure
- have diabetes
- have a low blood count
- have cancer
- have a history of stroke or “mini-stroke” (transient ischemic attack)
- drink alcohol or have problems with alcohol abuse. Alcohol can affect your TARO-WARFARIN dose and should be avoided
- plan to have any surgery or a dental procedure. Tell all of your healthcare professionals and dentists that you are taking TARO-WARFARIN. They should talk to the healthcare professional who

prescribed TARO-WARFARIN for you. This should be done before you have any surgery or dental procedure. Your TARO-WARFARIN may need to be stopped for a short time or you may need your dose adjusted

- are pregnant or planning to become pregnant Do not take TARO-WARFARIN during pregnancy. Use effective measures to avoid pregnancy while taking TARO-WARFARIN. This is very important because your unborn baby could be seriously harmed if you take TARO-WARFARIN while you are pregnant. Your baby could be born with birth defects or could die.
- are breastfeeding. TARO-WARFARIN may cause your baby to bleed. Talk to your healthcare professional about the best way to feed your baby. If you choose to breastfeed while taking TARO-WARFARIN, both you and your baby should be carefully monitored for bleeding problems
- have a catheter, a tube used to drain fluid from the body.
- have a deficiency in protein C or protein S, a condition where your body lacks the natural proteins that prevent blood clotting.
- have a vitamin K deficiency or are in a poor nutritional state.
- have a hereditary resistance to warfarin, the medicinal ingredient in TARO-WARFARIN.
- are taking streptokinase or urokinase, medicines used to dissolve blood clots.
- are 60 years of age or older. You may be more likely to experience certain side effects and may need a lower dose.

#### Other warnings you should know about:

- Tissue necrosis or gangrene (death of skin tissue): This can happen soon after starting TARO-WARFARIN. It happens because blood clots form and block blood flow to an area of your body. This can include “**purple toe syndrome**” where your toes may look purple or dark in colour and cause pain. You may also experience other symptoms such as rash, gangrene (lack of blood supply to a body part), intense pain in the leg, foot, toes, back or in your side. You may need medical care right away to prevent death or loss (amputation) of your affected body part. Talk to your healthcare professional right away if you notice symptoms of tissue necrosis such as rash and intense pain in the leg, foot, toes, back or side.
- Calciphylaxis: TARO-WARFARIN may cause calcium build up in small blood vessels of the fat and skin tissues (calciphylaxis). This can cause hardening of your blood vessels.
- TARO-WARFARIN should not be used if you have low platelet levels (**thrombocytopenia**) as this can be serious or life-threatening.
- **Anticoagulant-Related Nephropathy (ARN):** Some cases were reported in patients taking warfarin. It is a type of serious kidney damage caused by anticoagulant medicines. ARN causes bleeding in the kidneys, sometimes with the presence of blood in the urine. This leads to the kidneys being unable to function properly. Your healthcare professional may monitor the health of your kidneys during your treatment with TARO-WARFARIN. If you are experiencing symptoms of ARN during your treatment, tell your healthcare professional right away.

#### Blood Testing:

- To decide on the dosage of TARO-WARFARIN you need, your healthcare professional will regularly take a small amount of your blood. This will help to find out how fast your blood clots. This is often

recorded as an INR (International Normalized Ratio). INR tests are very important. They help your healthcare professional determine what dosage of TARO-WARFARIN is right for you.

- When you start taking TARO-WARFARIN, you may have INR tests every day for a few days, then periodically on a regular basis. Your healthcare professional will determine how often you need to have these tests done. **These INR tests and regular visits to a healthcare provider are very important for the success of TARO-WARFARIN therapy.** You will need to have these tests on a regular basis while you take TARO-WARFARIN. This will help keep your INR in the best range for your medical condition. Discuss with your healthcare professional the range that is right for you.

#### **Pregnancy and breastfeeding:**

- Talk to your healthcare professional if you are pregnant, think you might be pregnant or are planning to become pregnant.
- You should not take TARO-WARFARIN if you are pregnant. TARO-WARFARIN can cause birth defects in your baby or result in loss of the pregnancy or stillbirth.
- If you are a woman who is able to get pregnant you must use effective birth control while you are taking TARO-WARFARIN. Talk to your healthcare professional about the birth control options that are right for you.
- Talk to your healthcare professional if you are breastfeeding or planning to breastfeed. TARO-WARFARIN passes into breastmilk and may cause your baby to bleed. Talk to your healthcare professional about the best way to feed your baby. If you choose to breastfeed while taking TARO-WARFARIN, both you and your baby should be carefully monitored for bleeding problems.

**Surgery:** If you plan to have surgery or a dental procedure tell all of your healthcare professionals and dentists that you are taking TARO-WARFARIN. They should talk to the healthcare professional who prescribed TARO-WARFARIN for you before you have any procedure. You may need to stop taking TARO-WARFARIN for a short time before the procedure or you may need your dose adjusted.

- Certain illnesses can affect your TARO-WARFARIN therapy. Call your health professional if you:
  - are throwing up
  - have loose or runny stools
  - have an infection
  - have a fever.
- **Carry identification stating that you are taking TARO-WARFARIN.**

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

The following may interact with TARO-WARFARIN:

- Medicines to treat pain and inflammation called Non-steroidal anti-inflammatories (NSAIDs) such as ibuprofen, celecoxib, diclofenac and naproxen.
- Blood thinners such as aspirin, clopidogrel, apixaban, rivaroxaban, dabigatran, ticagrelor, prasugrel

and dipyridamole.

- Antidepressants in the class called selective serotonin reuptake inhibitors (SSRI) such as sertraline, paroxetine, fluoxetine, escitalopram and citalopram.
- Medicines to treat bacterial or antifungal infections such as amoxicillin, penicillin, azithromycin, ciprofloxacin, erythromycin, doxycycline, fluconazole, ketoconazole, voriconazole and itraconazole.
- Medicines to treat seizures such as phenytoin and phenobarbital.
- Certain medicines used to treat abnormal heart rhythms.
- Certain medicines used to treat conditions of the thyroid gland.
- Medicines in the class called corticosteroids used to reduce inflammation and immune response such as hydrocortisone and prednisone.
- Medicines in the class called statins used to lower cholesterol such as atorvastatin, lovastatin and simvastatin.
- Medicines in the class called proton pump inhibitors (PPIs) used to treat heartburn (reflux) or stomach ulcers such as pantoprazole, lansoprazole and omeprazole.
- Other medicines that contain warfarin. Warfarin is the medicinal ingredient in TARO-WARFARIN.
- Natural health products that may interact with TARO-WARFARIN include:
  - bromelains
  - coenzyme Q10
  - danshen (*Colocasia antiquorum*)
  - dong quai (*Angelica sinensis*)
  - echinacea
  - garlic
  - ginkgo biloba
  - ginseng
  - St. John's wort
- Grapefruit products that are part of your normal diet such as grapefruit, grapefruit juice or other grapefruit containing products.
- Cranberry products are part of your normal diet as cranberries, cranberry juice or other cranberry containing products.
- Other foods (eg, certain green vegetables such as broccoli which are rich in vitamin K) can also interact with TARO-WARFARIN
- Other medicines that contain warfarin. Warfarin is the active ingredient in TARO-WARFARIN.

#### **How to take TARO-WARFARIN:**

- Be sure to check that the tablet has "TARO-WARFARIN" written on one side and the correct numeric strength before you take it.
- **Take TARO-WARFARIN exactly the way your healthcare professional tells you and take it at the same time every day.**
- You can take TARO-WARFARIN either with food or on an empty stomach.
- Your dosage may change from time to time depending on your response to TARO-WARFARIN.
- Do not start, stop, or change any medicine except on advice of your healthcare professional.

- Eat a normal balanced diet. Avoid big changes in your diet. Talk to your healthcare professional before you go on a diet.
- Eat a consistent amount of green, leafy vegetables. Do not make big changes in your diet. These vegetables have high amounts of Vitamin K. The amount of vitamin K in your daily diet may affect therapy with TARO-WARFARIN.

**Usual dose:**

The dose of TARO-WARFARIN may be different for each patient. Your healthcare professional will monitor your INR levels and will decide what dose is best for you. This dose may change from time to time.

**Overdose:**

If you think you, or a person you are caring for, have taken too much TARO-WARFARIN, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

**Missed Dose:**

If you miss a dose of this medication, take it as soon as you remember on the same day, and talk to your healthcare professional. Do not take two doses at the same time on the next day to make up for a missed dose.

**Possible side effects from using TARO-WARFARIN:**

These are not all the possible side effects you may have when taking TARO-WARFARIN. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- abdominal pain including cramping
- diarrhea, gas, bloating
- nausea, vomiting
- bitter sour metallic taste, change in taste
- difficulty in swallowing
- bleeding gums
- itching, rash, redness
- red or purple spots on skin
- loss of hair in patches (alopecia)
- tiredness, fatigue
- lack of energy

- dizziness, headache
- feeling cold, chills, fever
- generally feeling unwell, paleness
- swelling of the hands, legs, or feet
- joint pain, muscle pain
- tingling or pricking sensation

TARO-WARFARIN affects blood clotting, so most side effects are related to bleeding.  
 TARO-WARFARIN can cause bleeding that can be serious and sometimes lead to death.

Your healthcare professional will work to keep your INR within a range that is right for you. This will help lower the risk of bleeding.

**Serious side effects and what to do about them**

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
<b>Unknown</b>			
<b>Adrenal hemorrhage</b> (bleeding from the adrenal glands): pain in the abdomen or sides, nausea, vomiting, dizziness, weakness, fatigue, muscle aches			√
<b>Allergic reaction:</b> difficulty swallowing or breathing, wheezing, feeling sick to your stomach and throwing up, hives or rash, swelling of the face, lips, tongue or throat			√
<b>Anemia</b> (decreased number of red blood cells): fatigue, loss of energy, looking pale, shortness of breath, weakness		√	
<b>Angina</b> (not enough oxygen to the heart muscle): squeezing, pressure, heaviness, tightness, chest pain, discomfort in the shoulder, arm, back, throat, jaw or teeth			√
<b>Anticoagulant-related nephropathy</b> (serious kidney damage caused by anticoagulant medicines): bleeding in the kidney sometimes with presence of blood in urine leading to inability of the kidneys to work properly.			√
<b>Blood pressure disorders:</b> dizziness, fainting, unconsciousness, shock (pale cold clammy skin, shallow rapid			√

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
breathing, anxiety, dry mouth, low urine output, dark urine)			
<b>Calciophylaxis</b> (accumulation of calcium in blood vessels, fat and skin tissues): intense pain, web-like purple, red or brown patches on the skin, particularly the abdomen, thighs and buttocks, blisters or ulcers		√	
<b>Embolism</b> (clots from blood and fat): cold arm or leg, no pulse and lack of movement of the arm or leg, pain in the affected area, numbness and weakness, shortness of breath, purple spots on the skin, fast heartbeat, fever, fatigue, weight loss, loss of appetite, muscle pain			√
<b>Eye hemorrhage</b> (bleeding in the eye): bright red patch on white part of the eye			√
<b>Gastrointestinal (GI) bleeding</b> (bleeding anywhere along the GI tract between mouth and anus): blood in vomit, black tarry stool, bright red blood in your stool or coming from rectum, rapid pulse, low blood pressure, low urine flow, confusion, weakness, dizziness			√
<b>Hemarthrosis</b> (bleeding into joint spaces): joint pain, swelling, redness, warmth, stiffness, reduced range of motion		√	
<b>Hepatic hemorrhage</b> (liver bleeding): vomiting blood, lightheadedness, pain in right upper abdominal region, blood in stool, fast heartbeat			√
<b>Intracranial hemorrhage</b> (bleeding in the brain): sudden, severe headache, confusion, nausea and vomiting, seizures, coma, loss of consciousness			√
<b>Kidney disorders</b> (acute kidney injury): blood in urine, decreased urine output, swelling in limbs, fatigue, shortness of breath, confusion, nausea		√	
<b>Liver disorders</b> (including hepatitis): nausea, fever, fatigue, vomiting, abdominal pain, loss of appetite, dark colored urine, light-colored stools, yellowing of the skin or whites of		√	

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
the eyes (jaundice)			
<b>Lung disorders:</b> bleeding from the nose, bleeding from the mouth, blood in sputum, difficulty breathing, cough, wheezing, shortness of breath, chest pain			√
<b>Pericardial hemorrhage</b> (bleeding in the sac surrounding the heart): shortness of breath, chest fullness, sharp chest pain that may get worse when breathing or lying down, palpitations, swelling in abdomen and legs, dizziness or lightheadedness			√
<b>Priapism</b> (prolonged painful erection): long-lasting (greater than 4 hours in duration) and painful erection of the penis			√
<b>Retroperitoneal hemorrhage</b> (bleeding into the area behind the abdominal lining): abdominal, upper leg or groin pain, shock (lightheadedness, dizziness, sweating, fast heartbeat)			√
<b>Skin reactions:</b> itching, hives, wheals at joints, red and warm swollen area of skin that spreads quickly, severe pain, large blisters which rupture easily			√
<b>Spinal hematoma</b> (blood around the spinal cord): pain, numbness, difficulty in walking, loss of bowel/bladder movement			√
<b>Splenic rupture</b> (burst or torn spleen): pain in the left upper abdominal area or left shoulder tip area		√	
<b>Tissue necrosis and gangrene</b> (including “ <b>purple toe syndrome</b> ”): intense pain in foot and leg, bluish purple discoloration of the toe, intense pain in the back or side, skin sores or ulcers, skin discoloration			√
<b>Vaginal hemorrhage:</b> bleeding between periods, bleeding after sex, large clots, heavy bleeding during your period		√	
<b>Rare</b>			
<b>Tracheal or tracheobronchial calcification</b> (hardening of the cartilage in the windpipe): recurrent infection,			√

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
breathlessness, cough, blood in sputum			

These are not all of the side effects of TARO-WARFARIN. For more information, ask your healthcare professional or pharmacist.

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

**Reporting Side Effects**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting ([www.canada.ca/drug-device-reporting](http://www.canada.ca/drug-device-reporting)) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

**Storage:**

- Store the tablets at room temperature (15 °C to 30 °C).
- Protect from light.
- Keep tablets in air tight container.
- Keep out of reach and sight of children.

**If you want more information about TARO-WARFARIN:**

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the (<https://health-product.canada.ca/dpd-bdpp/>); the manufacturer’s website at [www.taro.ca](http://www.taro.ca), or by calling 1-800-268-1975.

This leaflet was prepared by Taro Pharmaceuticals Inc.

Date of Authorization: 2026-04-08